抢占高潜力细分赛道，石药等药企拟设立合资公司破局

制药网2025-12-25

在医药行业创新转型加速与市场竞争日趋激烈的背景下，设立合资公司正成为药企整合资源、抢占细分高潜力赛道的重要抓手。业内表示，药企通过合资模式有利于实现优势互补、为自身发展注入新动能。如12月22日，石药创新制药股份有限公司(以下简称“石药创新”)发布公告称，拟与石药集团中奇制药技术 (石家庄)有限公司(以下简称 “中奇制药” ) 共同出资4.5亿元设立合资公司——石药集团润石生物科技 (石家庄) ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594225913?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 14:56","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2594225913","market":"hk","top_or_hot":-1,"title":"抢占高潜力细分赛道，石药等药企拟设立合资公司破局","media":"制药网","content":"<div>\n<p>在医药行业创新转型加速与市场竞争日趋激烈的背景下，设立合资公司正成为药企整合资源、抢占细分高潜力赛道的重要抓手。业内表示，药企通过合资模式有利于实现优势互补、为自身发展注入新动能。如12月22日，石药创新制药股份有限公司(以下简称“石药创新”)发布公告称，拟与石药集团中奇制药技术 (石家庄)有限公司(以下简称 “中奇制药” ) 共同出资4.5亿元设立合资公司——石药集团润石生物科技 (石家庄) ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225145847a6cd6dd8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>抢占高潜力细分赛道，石药等药企拟设立合资公司破局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n抢占高潜力细分赛道，石药等药企拟设立合资公司破局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 14:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225145847a6cd6dd8&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在医药行业创新转型加速与市场竞争日趋激烈的背景下，设立合资公司正成为药企整合资源、抢占细分高潜力赛道的重要抓手。业内表示，药企通过合资模式有利于实现优势互补、为自身发展注入新动能。如12月22日，石药创新制药股份有限公司(以下简称“石药创新”)发布公告称，拟与石药集团中奇制药技术 (石家庄)有限公司(以下简称 “中奇制药” ) 共同出资4.5亿元设立合资公司——石药集团润石生物科技 (石家庄) ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225145847a6cd6dd8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B5MMRT66.SGD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225145847a6cd6dd8&s=b","article_id":"2594225913","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225145847a6cd6dd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594225913","pubTimestamp":1766645795,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"无独有偶，10月30日，海正药业曾与圣兆药物签署合作协议，共同投资在台州市椒江区设立一家专注于复杂注射剂领域的合资公司。海正药业称，公司已将复杂注射剂作为实施差异化发展的重点领域，通过参与圣兆药物股票定向发行、与其投资设立合资子公司，符合公司在高端仿制领域的战略布局，有利于公司培育新的利润增长点。从行业发展趋势来看，药企设立合资公司具有深刻的行业逻辑。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","01093":"石药集团","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1191":"制药","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1515":"抗疫概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC"},"translate_title":"To seize the high-potential segmented track, CSPC and other pharmaceutical companies plan to set up joint ventures to break the situation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"在医药行业创新转型加速与市场竞争日趋激烈的背景下，设立合资公司正成为药企整合资源、抢占细分高潜力赛道的重要抓手。业内表示，药企通过合资模式有利于实现优势互补、为自身发展注入新动能。如12月22日，石药创新制药股份有限公司(以下简称“石药创新”)发布公告称，拟与石药集团中奇制药技术 (石家庄)有限公司(以下简称 “中奇制药” ) 共同出资4.5亿元设立合资公司——石药集团润石生物科技 (石家庄) 有限公司。合资公司将承接石药集团旗下全部GLP-1靶点等相关产品管线(包括但不限于临床前研究、已进入临床阶段以及申报上市阶段的管线)的技术以及后续研发和商业化，并通过自主开发、权益购买、管线引入等多种方式进一步拓展创新型代谢类药物相关管线的研发和商业化，丰富产品矩阵。公告称，成立新公司的动作高度契合公司长期发展战略，有利于实现优势互补，将业务进一步延伸至超重/肥胖和2型糖尿病等具有较大增长潜力的治疗领域。公司表示，本次交易构成关联交易，已获公司董事会及独立董事专门会议审议通过，无需提交股东大会批准。此举旨在把握代谢药物市场增长机遇，延伸业务至潜力治疗领域，提升整体竞争实力。据悉，目前石药集团至少有5款GLP-1靶点相关产品获中/美上市受理或以高达20亿美元的里程碑付款完成对外授权。无独有偶，10月30日，海正药业曾与圣兆药物签署合作协议，共同投资在台州市椒江区设立一家专注于复杂注射剂领域的合资公司。该合资公司将主要研发、生产及商业化11个复杂注射剂产品(含复杂注射剂仿制药和改良型新药)。海正药业称，公司已将复杂注射剂作为实施差异化发展的重点领域，通过参与圣兆药物股票定向发行、与其投资设立合资子公司，符合公司在高端仿制领域的战略布局，有利于公司培育新的利润增长点。据悉，本次双方合作提到的复杂注射剂，是指通过特殊技术制备的、具有复杂结构或递送系统的注射制剂，主要用于改善药物稳定性、靶向性或延长作用时间，如盐酸多柔比星脂质体与普通注射液相比，可降低不良反应发生率。本次总投资预计达23亿元，其中股东拟出资11亿元。从行业发展趋势来看，药企设立合资公司具有深刻的行业逻辑。当前，医药研发投入高、周期长、风险大的特点愈发凸显，单一企业往往难以独自承担全链条的研发与商业化压力。通过合资模式，药企可实现研发资源、生产能力、销售渠道等核心要素的互补，有效降低研发风险与运营成本，同时快速切入高潜力细分赛道，抢占市场先机。无论是石药集团聚焦的GLP-1创新药赛道，还是海正药业布局的复杂注射剂高端仿制赛道，均是市场需求旺盛、增长潜力巨大的领域，合资公司的设立有望推动资源向这些优质赛道集中，加速相关产品的研发与商业化进程。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594225913","isCrawlerRequest":true}